Janssen J - Search Results

1

Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia.

van der Werf I, Wojtuszkiewicz A, Yao H, Sciarrillo R, Meggendorfer M, Hutter S, Walter W, Janssen J, Kern W, Haferlach C, Haferlach T, Jansen G, Kaspers GJL, Groen R, Ossenkoppele G, Cloos J. van der Werf I, et al. Among authors: janssen j. Leukemia. 2021 Sep;35(9):2735. doi: 10.1038/s41375-021-01340-z. Leukemia. 2021. PMID: 34272482 Free PMC article. No abstract available.

2

Outcome of ICU treatment in invasive aspergillosis.

Janssen JJ, Strack van Schijndel RJ, van der Poest Clement EH, Ossenkoppele GJ, Thijs LG, Huijgens PC. Janssen JJ, et al. Intensive Care Med. 1996 Dec;22(12):1315-22. doi: 10.1007/BF01709544. Intensive Care Med. 1996. PMID: 8986479

3

Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells.

Ossenkoppele GJ, Stam AG, Westers TM, de Gruijl TD, Janssen JJ, van de Loosdrecht AA, Scheper RJ. Ossenkoppele GJ, et al. Among authors: janssen jj. Leukemia. 2003 Jul;17(7):1424-6. doi: 10.1038/sj.leu.2402979. Leukemia. 2003. PMID: 12835739 Clinical Trial. No abstract available.

4

[Ulcers on the legs and feet: a seldom recognised side effect of hydroxyurea].

Janssen JJ, Ossenkoppele GJ. Janssen JJ, et al. Ned Tijdschr Geneeskd. 2003 Aug 2;147(31):1517-20. Ned Tijdschr Geneeskd. 2003. PMID: 12924084 Dutch.

5

Secondary imatinib resistance associated with an aberrant bcr-abl fusion gene.

Janssen JJ, Hochhaus A, van Oostveen JW, Waisfisz Q, Schuurhuis GJ, Ossenkoppele GJ. Janssen JJ, et al. Leukemia. 2004 May;18(5):1020-1. doi: 10.1038/sj.leu.2403338. Leukemia. 2004. PMID: 15014529 No abstract available.

6

Identification of genes potentially involved in disease transformation of CML.

Janssen JJ, Klaver SM, Waisfisz Q, Pasterkamp G, de Kleijn DP, Schuurhuis GJ, Ossenkoppele GJ. Janssen JJ, et al. Leukemia. 2005 Jun;19(6):998-1004. doi: 10.1038/sj.leu.2403735. Leukemia. 2005. PMID: 15815727

7

Maintained immunogenicity of chronic myeloid leukemia-derived dendritic cells in the presence of imatinib mesylate: implication for vaccination regimens.

Westers TM, Janssen JJ, Houtenbos I, Snoijs NC, van de Loosdrecht AA, Ossenkoppele GJ. Westers TM, et al. Among authors: janssen jj. Leukemia. 2006 Jan;20(1):154-7. doi: 10.1038/sj.leu.2404043. Leukemia. 2006. PMID: 16307013 No abstract available.

8

High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome.

Chamuleau ME, van de Loosdrecht AA, Hess CJ, Janssen JJ, Zevenbergen A, Delwel R, Valk PJ, Löwenberg B, Ossenkoppele GJ. Chamuleau ME, et al. Among authors: janssen jj. Haematologica. 2008 Dec;93(12):1894-8. doi: 10.3324/haematol.13113. Haematologica. 2008. PMID: 19050070 Free article.

9

A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment.

Janssen JJ, Berendse HW, Schuurhuis GJ, Merle PA, Ossenkoppele GJ. Janssen JJ, et al. Am J Hematol. 2009 Oct;84(10):679-82. doi: 10.1002/ajh.21489. Am J Hematol. 2009. PMID: 19658186 Free article. No abstract available.

10

Chronic myeloid leukemia lysate-loaded dendritic cells induce T-cell responses towards leukemia progenitor cells.

Westers TM, van den Ancker W, Bontkes HJ, Janssen JJ, van de Loosdrecht AA, Ossenkoppele GJ. Westers TM, et al. Among authors: janssen jj. Immunotherapy. 2011 Apr;3(4):569-76. doi: 10.2217/imt.11.3. Immunotherapy. 2011. PMID: 21463196

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,451 results

Search Page